Current Funding Opportunities for Scientists

Lists of funding opportunities are updated weekly. New funding opportunities for scientists are distributed in the VPRI Update newsletter.

To submit funding opportunities, and/or be added to the VPRI Update mailing list, please send your request to VPRI@smh.ca.

Opportunities are categorized by Sponsor Type (Tri-Agency, Other Canadian, International & NIH). Filter opportunities by keyword (e.g. Sponsor Type, CIHR, user-supplied keyword, etc.) using the Search box at right.

Sponsor TypeFunding Program TitleAmount and DurationDescriptionDeadline
Tri-AgencyCIHR Pre-Announcement: Catalyst Grant: Towards Pan-Canadian Standards for Children and Youth Mental Health ServicesUp to $200,000 for 1 year. This will support research to inform standards specific to mental health and/or substance use health services for children, youth, and young adults (ages 0 to 25), including the perinatal period. Research relevant to the workforce or providers who support children, youth, young adults, and/or their caregivers/families in these sectors is also applicable (e.g., standards relevant to training).Anticipated Program Launch: June 2022
Tri-AgencyCIHR Team Grant: Mental Health in the Early Years (MHITEY) Implementation ScienceUp to $250,000 per year for up to 5 years.The goal is to fund implementation science research that enhances our understanding of how to improve the systematic and equitable implementation of evidence-based interventions for young children (i.e., girls, boys and gender diverse children ages 0-5) and their caregivers that address one or more of the following areas:
- Promotion of positive socio-emotional development and mental health in early childhood;
- Prevention of the development of early childhood mental health issues; and
- Treatment of young children living with or at risk of developing mental health issues through integrated, coordinated and person-oriented care.
June 23, 2022.
Tri-AgencyNew Frontiers in Research Fund (NFRF) 2022 Exploration CompetitionUp to $100,000 per year (plus $25,000 per year indirect costs) for up to 2 years.The goal of the Exploration stream is to inspire high-risk, high-reward and interdisciplinary research. Exploration grants support research that pushes boundaries into exciting new areas. New this competition, individuals can participate in only one application of the NFRF Exploration grants stream at a time, as either an NPI, co-PI or co-applicant. If you plan to apply, please let us know by email to VPRI@unityhealth.to.Notice of Intent (NOI): June 28, 2022. Please note that the NOI is not adjudicated.
Full Application: September 13, 2022.
NOTE: Submissions for all stages of all NFRF competitions must be submitted by no later than 10:00AM on the day of the deadline. This internal deadline is mandatory in order for ORA to approve the submission and forward it to NFRF.
Tri-AgencyCIHR Other: Planning and Dissemination Grants: Institute/Initiative Community Support (Summer 2022 Competition)Maximum varies by sponsoring Institute and Initiative. Ranges from $13,500-$50,000.This provides support for planning and/or dissemination activities (either virtual or in-person) consistent with the mandate of CIHR and relevant to CIHR Institutes and Initiatives.July 7, 2022.
Tri-AgencyCIHR Team Grant: CIHR-JDRF Type 1 Diabetes (T1D) and Precision MedicineUp to $875,000 per year for up to 4 years, for a total of $3,500,000 per grant.This funding opportunity will support projects relevant to precision medicine and T1D in the following research areas:
- Research spanning genes, metabolic factors, and physiologic characterization, focused on understanding heterogeneity utilizing new technologies, such as multi-omics and machine learning
- Biomarker validation, standardization, and application to better understand T1D disease risk, development and pathogenesis, including progression
- Characterization of different endotypes of T1D to guide improved clinical care, research, or trial stratification
- Understanding heterogeneity of disease in different races and ethnicities and in Indigenous Peoples (First Nations, Inuit and Métis)
This funding excludes research on stem cell–based therapies for the treatment of T1D, early biomarker discovery, and research focused on complications.
Registration: July 21, 2022.
Application: August 23, 2022.
2023 NSERC Discovery Grant--The Discovery Grants program assists in: promoting and maintaining a diversified base of high-quality research capability in the natural sciences and engineering in Canadian universities; fostering research excellence; and providing a stimulating environment for research training. Note that all applications must be submitted through U of T; contact: keti.dzamova@utoronto.ca.Notice of Intent: August 1, 2022.
Full Application: November 1, 2022.
Tri-AgencyCIHR Project Grant: Fall 2022--CIHR has announced their timelines for the Fall 2022 Project Grant competition. More information to follow after the competition is launched on July 5, 2022.Registration: August 17, 2022.
Application: September 14, 2022.
Tri-AgencyCIHR Operating Grant: Psilocybin-assisted PsychotherapyUp to $500,000 per year for up to 2 years.This funding opportunity will support phase 1 or 2 randomized clinical trials relevant to psilocybin-assisted psychotherapy in the treatment of the following research areas:
- Substance use dependence or substance use disorders
- Major Depressive Disorder (MDD) or treatment resistant depression
- End-of-life psychological distress in patients with advanced-stage cancer
Registration: September 6, 2022.
Application: October 4, 2022.
Tri-AgencySSHRC Partnership Engage GrantsBetween $7,000 and $25,000.These grants provide short-term and timely support for partnered research activities that will inform decision-making at a single partner organization from the public, private or not-for-profit sector.September 15, 2022 and December 15, 2022.
Tri-AgencyCIHR INMD Training and Community Support Grant (2022/2023)Up to $50,000.This will support INMD research communities, including researchers and Partner Organizations (i.e., voluntary health sector organizations such as non-profit organizations, professional organizations and registered charities), to build training programs in research domains largely and directly relevant to the Institute's mandate. It may be used to develop and support training curriculum, training and career development meetings and events, or mentoring activities.September 30, 2022.
Tri-AgencyCIHR Catalyst Grant: Policy Research for Health System TransformationUp to $150,000 per year for 1 year.This includes retrospective policy evaluations or prospective policy development/implementation that generate evidence to inform macro-level policies to support high-performing health care and public health systems in Canada with the aim of advancing the Quadruple Aim – improved population health outcomes, better patient and provider experience, and increased value – and health equity (sometimes referred to as the Quintuple Aim). In addition, it will provide support for a supplemental knowledge mobilization synthesis project to coordinate and lead a synthesis of the policy research approaches used by the policy research teams, of the policy issues and of their findings/options, to support learning across all teams.October 4, 2022.
Tri-AgencyCIHR Pre-announcement: Transforming Health with Integrated Care (THINC) - Implementation Science Teams GrantsUp to $400,000 per year for up to 5 years.This focuses on improving our understanding of how to implement, evaluate, adapt, and/or spread/scale evidence-informed integrated care policies and interventions that encompass intersectoral collaborations within and/or beyond the formal health care delivery system in order to advance the Quadruple Aim and health equity (sometimes known as the Quintuple Aim).Anticipated Timelines*
CIHR Webinar: July 13, 2022 at 2 – 3:30 pm EST
Full Application Deadline: November 15, 2022.
*These timelines are estimates and subject to change.
Tri-AgencyCIHR Operating Grant: Diabetes, Psychosocial Health, Prevention and Self-ManagementUp to $250,000 per year for up to 4 years, for a total of $1,000,000 per grant.This will support research into approaches that will build on successful models of care, knowledge mobilization, and optimization of self-management. Specific to T1D, this funding opportunity will support research that is focused on interventions and models of care that address psychosocial issues and mental health disorders in people with T1D and thereby improve mental health and associated quality of life and/or clinical outcomes. Specific to T2D, this funding opportunity will support psychosocial health research focused on prevention and treatment in youth and young adults, with a focus on Indigenous and racialized, ethnocultural and low socio-economic status communities that are disproportionately affected by T2D. November 1, 2022.
Tri-AgencyTri-Council Special Response Fund for Trainees Ukraine (SRFT-Ukraine)Master's level: Up to $20,000; Doctoral level: Up to $25,000; Postdoctoral level: Up to $45,000. Support can be requested for a period of up to 12 months. Requested amounts will be pro-rated to reflect the expected duration of the support.This limited-time fund is to initiate or maintain the employment or financial support of trainees who are directly impacted by the crisis in Ukraine. CIHR- NSERC- and SSHRC-funded grant holders can apply. This additional funding for grant holders will support trainees, defined as graduate students or postdoctoral researchers through salaries and stipends.Continuous intake until December 22, 2022.
Tri-AgencyNSERC Alliance/Mitacs Accelerate Grants--This is for applicants seeking support from both an Alliance grant and Mitacs Accelerate, to apply through a single application submission and review process. Applicants who wish to include Mitacs Accelerate internships in their Alliance application should contact their local Mitacs business development representative to obtain the NSERC/Mitacs joint application form.Ongoing
Tri-AgencyNSERC Alliance Grants$20,000 to $1 million per year for 1-5 yearsSupport university researchers to collaborate with partner organizations, which can be from the private, public or not-for-profit sectors.
NOTE: All NSERC grant applications must be submitted through the University of Toronto Research Services Office.
No Deadline
Tri-AgencyNSERC Alliance International- Catalyst Grants: $25,000 for 1 year.
- Collaboration Grants: Up to $100,000 per year for up to 3 years.
These are for Canadian university researchers working in the natural sciences and engineering in partnership with international collaborators from the academic sector. The overall objectives are to: 1) allow Canadian researchers to initiate the development of international collaborations; and 2) provide support for Canadian researchers participating in international collaborative projects of global importance and benefit to Canada. The applicant and any Canadian co-applicants must have an active NSERC peer-reviewed grant, as primary applicant, at the time of application.
NOTE: All NSERC grant applications must be submitted through the University of Toronto Research Services Office.
No Deadline
Other CanadianThe Manchester-Melbourne-Toronto (MMT) Research FundUp to ~$22,000 for bilateral or up to ~$33,000 for trilateral for 18 months.This supports proposals that will lead to long-term research collaborations with a view to enabling principal investigators to subsequently apply for external funding to support the next phase of their joint research. It is open to applications from all research areas. Projects must include research team participants from a minimum of two of the three institutions and must be led by, or include in a significant role, Early Career Researchers. U of T applicants must hold a continuing faculty appointment.June 16, 2022.
Other CanadianBrain Tumour Foundation of Canada (BTFC) Research GrantsUp to $25,000 for up to 2 years.BTFC seeks outstanding researchers conducting quality brain tumour research. All such proposals will be given consideration. Additionally, we are interested in receiving innovative research proposals which incorporate novel or original concepts that have the potential to make a difference and projects that involve collaboration. Adult and pediatric brain tumour projects in basic, clinical or translational research will be considered.June 17, 2022.
Other CanadianCanadian Cancer Society (CCS): Various OpportunitiesPlease see individual funding opportunity description.CCS Breakthrough Team Grants: Transforming Low Survival Cancers: This funding opportunity will bring together interdisciplinary teams to develop innovative approaches to transform outcomes and reduce the number of Canadians dying from six low-survival cancers (pancreas, oesophagus, brain, lung, liver, and stomach). Value: Up to $1.5M per year over 5 years.
CCS Health Equity Research Grants- Advancing a More Accessible and Inclusive Cancer Care System: Supports research projects that seek to advance cancer-related health equity. Projects must be collaborative, co-created by people both affected by cancer and by structural marginalization, and designed to address the systemic, structural, and institutional factors that sustain health disparities in Canada. Value: Up to $300,000 per grant over 3 years. Deadlines: Abstract Registration: July 20, 2022; Full Application (by invitation): September 8, 2022.
CCS Breakthrough Team Grants: Transforming Low Survival Cancers: Expression of Interest: June 22, 2022; Registration: July 26, 2022; Full Application: October 19, 2022.
CCS Health Equity Research Grants - Advancing a More Accessible and Inclusive Cancer Care System: Abstract Registration: July 20, 2022; Full Application (by invitation): September 8, 2022.
Other CanadianTerry Fox Research Institute (TFRI): Various OpportunitiesPlease see individual funding opportunity description.Terry Fox New Investigator Award: This provides research operating grants to support outstanding new researchers develop their careers as independent research scientists or clinician scientists. Funding is targeted at high-quality biomedical, clinical and/or translational research, providing information that may form the basis of innovative cancer prevention, diagnosis and/or treatment. Value: Up to $150,000 per year for 3 years.
Terry Fox New Frontiers Program Project Grants: This supports multidisciplinary program projects that contribute to the discovery and new knowledge that has the potential to transform cancer diagnosis, treatment and/or understanding of cancer biology. Value: New applications: Up to $400,000 in the first year and up to $600,000 per year for the 3 subsequent years.
Terry Fox New Investigator Award: Registration of Intent: June 30, 2022; Full Application: September 9, 2022.
Terry Fox New Frontiers Program Project Grants Letter of Intent: August 2, 2022; Full Application (by invitation): November 23, 2022.
Other CanadianPublic Health Agency of Canada (PHAC): Spring 2022 Dementia Community InvestmentUp to $250,000 per year for up to 4 years.This call for proposal focuses on enhancing well-being by improving health behaviours of people living with dementia and family/friend caregivers.Letter of Intent: June 30, 2022.
Full Application (by invitation): Fall 2022.
Other CanadianCall for University of Sydney (USyd) – U of T Partnership Collaboration Awards (PCA)AUD $10,800 & CAD $10,000.Proposals must align with the UN Sustainable Development Goals (SDG); proposals with a focus on research related to making cities inclusive, safe, resilient and sustainable, in alignment with SDG 11 are strongly encouraged. Please direct questions to kevin.rowley@utoronto.ca.July 1, 2022.
Other CanadianOntario Brain Institute (OBI): Event Funding ProgramUp to $5,000.The program especially looks to support events that embody OBI’s principles of integration and collaboration, particularly across brain health or brain disorder topics, organizations, and stakeholder groups.July 8, 2022; October 28, 2022.
Other CanadianAlzheimer Society Research Program: Proof of Concept (PoC) GrantUp to $100,000 for up to 3 years.This funds established researchers in conducting innovative, high-risk and high-reward approaches to dementia researchLetter of Intent: July 11, 2022.
Application (by invitation): November 4, 2022.
Other CanadianOntario Institute for Cancer Research (OICR) Cancer Therapeutics Innovation Pipeline (CTIP)Up to $150,000 per year for up to 1 or 2 years.This will help create a pipeline of validated cancer targets and first-in-class or best-in-class, novel, selective lead molecules (small molecules or biologics) to attract partnerships and/or investment for further preclinical and clinical development.Letter of Intent: July 13, 2022.
Full Application (by invitation): October 5, 2022.
Other CanadianU of T Data Sciences Institute (DSI) Catalyst GrantUp to $100,000 for 1 or 2 years.Funds multidisciplinary teams focused on the development of novel statistical or computational tools or the use of existing methodology in innovative ways to address questions of major societal importance and effect positive social change. A proportion of funds are prioritized for research projects in the areas of (1) Social Inequity and (2) Data Reproducibility. Teams must include one domain expert and one methods expert, or two methods experts from different fields working together.Letter of Intent: July 15, 2022.
Application (by invitation): November 4, 2022.
Other CanadianCanadian Blood Services (CBS) Blood Efficiency Accelerator ProgramUp to $30,000 for 1 year.The objective is to improve the efficient and appropriate utilization of blood products, while maintaining the safety of the blood system. To achieve this objective, the Program will support innovative research projects that seek new knowledge or accelerate the application of existing knowledge. All project teams require at least one CBS employee.July 15, 2022.
Other CanadianDiabetes Canada End Diabetes AwardsUp to $100,000 per year for up to 3 years.The objectives of the End Diabetes Awards are: 1) To support researchers in the discovery of the biomedical, clinical, health services, and/or population health factors that lead to the onset and progression of all types of diabetes and related complications. 2) To develop solutions aimed at the prevention, management, and finding a cure for people living with diabetes.July 15, 2022.
Other CanadianOntario HIV Treatment Network (OHTN): HIV Endgame Funding Program Please see individual funding opportunity description.Winston Husbands Leadership Award in Strengthening the Response to HIV Among Black Communities: Salary support for emerging Black scholars, knowledge users, and service providers who work collaboratively with community stakeholders to understand and address the impact of HIV on African, Caribbean, and Black communities in Ontario. Value: Up to $75,000 per year for up to 2 years. Deadline: July 18, 2022.
Junior Investigator Grant: Salary support for emergent leaders in HIV inquiry who are preparing to establish a HIV program of data, evidence-sharing, and impact. Value: Up to $40,000 per year for up to 2 years.
Game Changer Grants-Breaking New Ground Grant: This funding stream supports the piloting, evaluation, or scale up of HIV interventions. Value: $50,000-$150,000 per year for up to 2 years.
Game Changer Grants-Implementation Science Grant: This funding stream will support implementation science initiatives that will contribute to a rapid learning system for HIV. Value: $150,000-$250,000 per year for up to 3 years.
Deadlines:
Letter of Intent: July 18, 2022.
Full Application (by invitation): October 17, 2022.
Incubator Grant: Project funding to establish high-risk, high-reward initiatives that will test, evaluate, and scale up innovative interventions and effective programs and services. Value: Up to $50,000-$300,000 per year for up to 2 years. Deadlines: Letter of Intent (LOI): Every first Friday of the month; Full Application (by invitation): As per LOI notification letter.
Winston Husbands Leadership Award in Strengthening the Response to HIV Among Black Communities: July 18, 2022.
Junior Investigator Grant, Game Changer Grants-Breaking New Ground Grant, Game Changer Grants-Implementation Science Grant: Letter of Intent: July 18, 2022; Full Application (by invitation): October 17, 2022.
Incubator Grant: Letter of Intent (LOI): Every first Friday of the month; Full Application (by invitation): As per LOI notification letter.
Other CanadianGairdner Ontario Programs Call For Proposals 2022Range from $5,000 - $25,000 per event.This will fund events that promote excellence and involvement in science in the province of Ontario. Events should are unique, free or low cost to attend, and represent the Gairdner dedication to excellence in research in the fields of human biology and medicine. This program is not intended to support annual meetings, administrative costs or as a research grant of any kind. Submissions must be submitted at least 6 weeks in advance for most events, and at least 8 weeks for a symposium level event.October 1, 2022.
Other CanadianMitacs Accelerate: Eligibility and New Program Updates--Options and enhancements include expanding eligibility for both interns and external sponsoring partners, and increasing support levels for some partners.

Mitacs Accelerate-Expanded Eligibility Criteria: Mitacs can now support undergraduate students as interns on a Mitacs Accelerate grant. In addition, municipalities and hospitals are now considered to be eligible partner organizations for Mitacs Accelerate

Accelerate Industrial Post-Doctoral Fellowship-New Funding Model: This funding stream provides $60,000/year for a post-doctoral fellow, where the partner organization must contribute $30,000 plus applicable taxes per year. Details here: Link.

Mitacs and National Research Council (NRC) collaborative funding stream for R&D projects: Support for 250 graduate and post-graduate student internships within the NRC's Challenge and Supercluster support programs. Details here: Link.
--
Other CanadianNew Mitacs Initiatives and Opportunities--Mitacs Parterships with Municipalities: Professors, postdoctoral fellows, graduate students, college students and undergraduate students can now put their talent to work on a collaborative research project at a municipality that needs your expertise. Canadian municipalities of all sizes are now eligible partners for co-funded projects involving post-secondary researchers through Mitacs programs. Details here: Link.

Mitacs Partnerships with Hospitals: This initiative empowers Canadian hospitals no matter the size, by providing access to the brightest post-secondary researchers and funding for innovative projects. Whether you are a hospital administrator looking to collaborate with experts across a myriad of disciplines or an academic whose research could benefit a hospital, Mitacs can help. Details here: Link.

Indigenous Pathways Initiative: Projects are a minimum of four months in duration - they can be longer - and now Indigenous-owned businesses and organizations’ contribution is only 25% of the cost of projects that have an Indigenous partner organization and/or an intern who is Indigenous. Details here: Link.
--
Other CanadianUniversity of Toronto Institutional Strategic Initiatives (ISI)From $50,000-$300,000 per year for up to 3 years.ISI awards are intended to establish research capacity in high-priority areas, with the goal of realizing transformational impacts on issues of societal importance. Proposed investigator-initiated initiatives must meet the following key criteria: 1) Address a significant challenge and associated research questions that requires an interdisciplinary approach; 2) Matching funds secured from three or more Academic Divisions; 3) Path to sustainability demonstrated by a clear opportunity for external funding. Ongoing
Other CanadianCollaboration Opportunities: National Research Council Canada (NRC) Challenge Programs--The NRC offers potential opportunities for collaboration in the following areas:

- Aging in Place
- Artificial Intelligence for Design
- Disruptive Technology Solutions for Cell and Gene Therapy
- High-throughput and Secure Networks
- Pandemic Response

Potential collaborators can register their interest to work with NRC on the Challenge Programs website.
Ongoing
Other Canadian Government of Canada: CanExport for Innovators Maximum of $75,000 Specifically designed to promote and enhance Canada's international innovation efforts. Eligible expenses may include international and local travel, accommodation, meals, meeting costs, legal fees to support formalized partnerships, and other costs related to international collaboration.

Applications must be submitted at least 8 WEEKS prior to the anticipated start date of the activities.
Continuous
Other CanadianWeston Brain Institute: Early Phase Clinical Trials: CanadaUp to $1,500,000 per project for up to 4 yearsFunding for clinical trials and/or clinical trial sub-studies with excellent preliminary data.Rolling deadline
Other CanadianPhysicians' Services Incorporated (PSI) Foundation: Health Research Grant & New Investigator GrantHealth Research Grant: Up to $250,000 for 3 years.

New Investigator Grant: Up to $300,000 for 3 years.
Areas of Support: clinical research, medical education research, health systems research. Applicant must be a College of Physicians and Surgeons of Ontario licensed MD. New Investigators must be within five years of their first academic appointment. Rolling deadline
Other CanadianTelus FundsVariousFor entertaining and engaging web series with the potential to positively impact families and friends providing care for loved ones struggling with a health condition.Various
Other CanadianOntario Centre of Innovation (OCI) Voucher for Innovation and Productivity (VIP) Program Minimum of $20,000 up to a maximum of $150,000 per year towards the direct costs of research (Industry Partner contribution has to be minimum of 1:1 cash match to the OCE contribution, where at least 50% must be spent at the post-secondary institution.)This program helps companies develop, implement and commercialize technical innovations by supporting partnerships between Ontario's industry and publicly funded post-secondary institutions and research hospitals. VIP projects are intended to generate economic benefit for companies in Ontario (including job creation/retention, new revenue generation, investment attraction, cost savings, value chain development), in the short-to-medium term (e.g. within three years of project completion).

If you are interested, please contact Samar Saneinejad (Samar.Saneinejad@unityhealth.to).
No Deadline
InternationalFY22 Peer Reviewed Orthopaedic Research Program (PRORP): Various OpportunitiesPlease see individual funding opportunity description.Applied Research Award: Supports applied research applications focused on advancing optimaltreatment and restoration of function for individuals with musculoskeletal injuries sustained during combat, combat-related activities, and non-battle injuries that impact unit readiness and the ability to return to duty/work. Value: Up to USD $725,000 for up to 3 years.
Clinical Trial Award: Supports rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of military combat-related orthopaedic injuries or non-battle injuries that significantly impact unit readiness and return to duty/work rates. Value: Research Level 1: Up to USD $2.5M for up to 4 years; Research Level 2: Up to $3.0M for up to 4 years.
Clinical Translational Research Award: Supports high-impact and/or new/emerging clinical research that may or may not be ready for a full-scale randomized controlled clinical trial. Value: Up to USD $1.5M for up to 4 years.

Pre-Application: June 16, 2022.
Application: September 13, 2022.
InternationalJDRF Clinical trials and mechanistic clinical studies to advance adjunctive therapies for glucometabolic control in type 1 diabetes (T1D)Clinical trial: Up to USD $2M for up to 3 years; Mechanistic clinical study: Up to USD $1M over up to 2 years.This is intended to support (1) clinical trials testing therapies- novel or repositioned, approved or in clinical development- for glucometabolic control in T1D, or (2) mechanistic clinical research to inform a better understanding of T1D glucometabolic imbalances to enable future therapy development.Letter of Intent: June 21, 2022.
Application: August 23, 2022.
InternationalUS Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY22 Rare Cancers Research Program (RCRP)Please see individual funding opportunity description.CDMRP will follow the definition of rare cancer as an incidence of six or fewer cases per 100,000 people per year in the US.
Idea Development Award: Preliminary data with disease-specific rationale to support the feasibility of the research hypotheses and research approaches are required. Focus Areas: Biology and Etiology; Research Model; Therapy. Value: Up to USD $350,000 for up to 3 years.
Resource and Community Development Award: Supports development of platforms for multiple rare cancers, to allow sharing of data, bio-specimens, and resources. Value: Up to USD $600,000 for up to 3 years.
Concept Award: Supports innovative, high-risk/high-reward research. Proof-of-concept is the anticipated outcome.Must address one or more of the following Focus Areas: Biology and Etiology; Research Model; Therapy. Value: Up to USD $100,000 for up to 1 year
Idea Development Award: Pre-Application: June 22, 2022; Application: September 30, 2022.
Resource and Community Development Award :Pre-Application: June 22, 2022; Application: September 30, 2022.
Concept Award: Pre-Application: July 18, 2022; Application: August 29, 2022.
InternationalUS Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY22 Kidney Cancer Research Program (KCRP): Concept AwardUp to USD $100,000 for up to 1 year. Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer. Funding for clinical trials not allowed. Pre-Application: June 23, 2022.
Application: July 14, 2022.
InternationalUS Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY22 Multiple Sclerosis Research Program (MSRP)Please see individual funding opportunity description.The CDMRP has pre-announced the following FY 2022 opportunities. Please see details of these at the MSRP link.
Clinical Trial Award: Funding Level 1 supports early-phase, proof-of-principle clinical trials to demonstrate feasibility or inform the design of more advanced trials, or other clinical trials that are appropriate for this Funding Level. Value: Up to USD $1.6M total costs for up to 3 years. Funding Level 2 supports larger-scale clinical trials at phase 1 or 2 that seek to show preliminary evidence of safety or efficacy (benefit on clinical or paraclinical outcomes) in relevant patient populations. Value: Up to USD $4.5M total costs for up to 4 years.
Early Investigator Research Award: The applicant must be involved in a postdoctoral training or medical residency program and possess at least 1 and up to 4 years continuous postdoctoral research experience; and commit at least 50% of their effort towards project. Value: Up to USD $320,000 total costs for up to 2 years.
Exploration - Hypothesis Development Award: Supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the MS research field. Value: Up to USD $250,000 total costs for up to 2 years.
Investigator-Initiated Research Award: Supports highly rigorous, high-impact research with the potential to make an important contribution to MS research and/or patient care. Clinical trials not allowed. Value: Up to USD $1.0M total costs for up to 3 years.
Clinical Trial Award: Pre-Application (Preproposal): June 23, 2022; Application: October 3, 2022.
Early Investigator Research Award: Pre-Application (Letter of Intent): August 2, 2022; Confidential Letters of Recommendation: October 6, 2022; Application: October 3, 2022.
Exploration - Hypothesis Development Award: Pre-Application (Preproposal): June 23, 2022; Application: October 3, 2022.
Investigator-Initiated Research Award: Pre-Application (Preproposal): June 23, 2022; Application: October 3, 2022.
InternationalUS Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP): FY22 Combat Readiness - Medical Research Program (CRRP) Rapid Development and Translational Research Award (RDTRA)Up to USD $2.2M total costs for up to 2 years; with Option for an additional USD $1.0M in total costs for up to 1 additional year.Proposed research must address at least one of the FY22 CRRP Focus Areas: Solutions to enhance Warfighter readiness; Solutions to enhance combat care delivery throughout the far-forward environment; Wound care solutions for complex trauma and tissue regeneration that span the operational medical care continuum or roles of care (e.g., acute through chronic care). Please see Focus Area details at the CRRP webpage.Pre-Application (Preproposal): June 23, 2022.
Application: September 14, 2022.
InternationalJDRF Early-career patient-oriented diabetes research awardsUp to USD $200,000 per year for up to 5 years. This is intended for clinical researchers who have received their first faculty-level appointment less than 5 years before the submission date. Applicants must have an MD, MD-PhD or PsyD, hold an appointment or joint appointment in a subspecialty of clinical medicine in a clinical department, and conduct human clinical research. Applications in the area of COMPLICATIONS will not be accepted. Applications in Psychosocial and Behavioral Health are welcome.June 29, 2022.
InternationalInternational Center for Responsible Gaming (ICRG) 2022 Grants ProgramUp to USD $75,000 per year for up to 24 months.These grants are to explore the etiology, prevention and treatment of gambling disorder, and the development and evaluation of responsible gambling strategies. June 30, 2022.
InternationalSociety of Interventional Radiology (SIR) Foundation: Various OpportunitiesPlease see individual funding opportunity description.Academic Transition Grant: Designed for interventional radiologists over the age of 40 who have recently begun academic careers after spending several years in non-academic practice. Value: Up to USD $25,000 for up to 1 year.
Dr. Ernest J. Ring Academic Development Grant: Designed to provide support to junior interventional radiology faculty members early in their academic careers to allow time for the conduct of research. Applicants must be within the first five years of their initial faculty appointment after having completed all of the formal training. Only applicants holding a position up to and including assistant professor level at the time will be considered. Value: Up to USD $75,000 per year for 2 years.
Funding Source Development Grant: This supports projects in clinical research areas important to the advancement of interventional radiology and patient care that align with SIR Foundation's clinical research goals. Value: Up to USD $25,000 for up to 1 year.
Pilot Research Grant Program: Funds research in areas identified by SIR Foundation as important to the advancement of interventional radiology and patient care. Value: Up to USD $35,000 for up to 1 year.
Academic Transition Grant: Proposal Development Form: June 30, 2022; Pre-Review: September 20, 2022; Application: January 15, 2023.
Dr. Ernest J. Ring Academic Development Grant: Proposal Development Form: June 30, 2022; Pre-Review: September 20, 2022; Application: January 15, 2023.
Funding Source Development Grant: June 30, 2022; January 15, 2023.
Pilot Research Grant Program: Proposal Development Form: June 30, 2022; Pre-Review: September 20, 2022; Application: January 15, 2023.
InternationalTreeFrog Therapeutics Stem Cell Spaceshot GrantUSD $100,000 for 12-24 months.This is a contest is to support bold scientists willing to explore uncharted territories for a research project in the field of stem cell biology. Eligible topics are: 1. Progressing stem cell culture and cell therapy products through biomimetic strategies; 2. Upgrading stem cell-products and manufacturing processes using new technologies and scientific approaches; 3. Improving the quality control and safety profile of stem cells and stem cell-derived transplants; 4. Enhancing the engraftment, integration and long-term survival of stem-cell derived transplants.June 30, 2022.
International
American Psychological Foundation (APF): Various Opportunities
APF/Division 39 Grant: USD $7,000.
Marian R. Stuart Grant: Up to USD $20,000.
David H. and Beverly A. Barlow Grant:Up to USD $7,500.
NOTE: The above list includes those grants valued at least USD $5,000. Please see the APF website for other opportunites valued less than USD $5,000.
APF/Division 39 Grant: Supports efforts in education, research, and service that advance and encourage the field of psychoanalysis.
Marian R. Stuart Grant: Support to further the research, practice, or education of an early career psychologist on the connection between mental and physical health, particularly for work that contributes to public health. Applicant must be an early career researcher (no more than 10 years postdoctoral).
David H. and Beverly A. Barlow Grant: Supports innovative basic and clinical research on anxiety and anxiety-related disorders. Applicant must be a graduate student or early career researcher (no more than 10 years postdoctoral).
APF/Division 39 Grant: June 30, 2022.
Marian R. Stuart Grant:July 1, 2022.
David H. and Beverly A. Barlow Grant:September 15, 2022.
InternationalParalyzed Veterans of America (PVA) Research Foundation: Various OpportunitiesUp to USD $75,000 for 1 year or up to $150,000 for 2 years.PVA supports innovative research that improves the lives of those with spinal cord injury and disease (SCI/D).
- Basic Science: Laboratory research in the basic sciences to find a cure for SCI/D.
- Clinical: Clinical and functional studies of the medical, psychosocial and economic effects of SCI/D, and interventions to alleviate these effects.
- Design and Development: Of assistive technology for people with SCI/D, which includes improving the identification, selection and utilization of these devices
July 1, 2022.
InternationalEmbassy of the United States of America - Canada (U.S. Mission in Canada) Public Affairs Section (PAS): Combatting COVID-19 Grant ProgramBetween USD $15,000-$100,000 for up to 24 months.
This invites proposals that that strengthen the bilateral ties between the U.S. and Canada and support the Roadmap for a Renewed U.S.-Canada Partnership Pillar Combatting COVID-19, including, but not
limited to:
- Programs and initiatives to combatting mis- and dis-information around COVID-19 and vaccinations and promote the importance of science-based public health measures in response to the pandemic.
- Messaging, information, and educational programs and campaigns that engage youth and underserved communities, and that address information and other disparities between communities and rural and urban audiences.
July 6, 2022.
InternationalBaxter Investigator Initiated Research (IIR) Grants: Various Opportunities--Advanced Surgery: the focus is on all products within Advanced Surgery that can address challenges faced during surgical procedures; specifically, hepatic, pancreatic, general surgery, lung, bariatric, cardiovascular, microvascular, colorectal, neurologic and spine related procedures.
Nutrition: the focus is on clinical outcomes, and/or health economic benefits, and/or impact of various nutrition formulations and/or compounding devices.
Medication Delivery: The focus is to contribute to scientific knowledge in topics of monitoring, drug delivery, infusion therapy, IV workflow management, fluid management, or optimizing patient outcome.
Pharmaceuticals: The focus is on Desflurane, injectable IV medications, and CONTRAFluran.
Acute Therapies: The focus is on blood purification including diagnostics/biomarkers, including preliminary prospective studies on the value of biomarkers in sepsis and other multi organ syndromes; ECCOR/PrismaLung+, CRRT, AKI Diagnostics/Nephroclear.
Renal Care: The focus is to augment the knowledge on Baxter Renal Care therapies through high-quality clinical and health-economic research in areas of individualized patient-centered care, time on therapy, patient experience, clinical outcome, and total cost of care.
Advanced Surgery: July 7, 2022; September 7, 2022.
Nutrition: July 7, 2022; September 7, 2022.
Medication Delivery: July 14, 2022; September 14, 2022.
Pharmaceuticals: July 14, 2022; September 14, 2022.
Acute Therapies: July 14, 2022; September 14, 2022.
Renal Care: July 21, 2022; September 21, 2022.
InternationalUS Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP): FY22 Chronic Pain Management Research Program (CPMRP): Various OpportunitiesPlease see individual funding opportunity description.Clinical Exploration Award: Supports proof-of-principle pilot studies, clinical trials, and correlative studies with the potential to resolve current clinical barriers. Studies evaluating opioid-based therapeutic interventions are not allowed. Value: Up to USD $250,000 for up to 2 years.
Investigator-Initiated Research Award: Supports innovative research that will make an original and important contribution to the field of research, patient care, and/or quality of life. Clinical trials are not allowed. Value: Up to USD $900,000 for up to 4 years.
Translational Research Award: Supports translational research that will accelerate the movement of efficacious, evidence-based ideas into clinical applications. Studies evaluating opioid-based therapeutic interventions are not allowed. Value: Up to USD $1.4M for up to 4 years.
Pre-Application (Preproposal): July 12, 2022.
Application: October 13, 2022.
InternationalUnited States Department of Defense (DoD) Congressionally Directed Research Programs (CDMRP): FY 2022 Peer Reviewed Cancer Research Program (PRCRP): Various OpportunitiesPlease see individual funding opportunity description.To be considered for funding, applications for the FY22 PRCRP must address at least one of the FY22 Topic Areas listed on the opportunity website. Research applications in the areas of breast, kidney, lung, prostate, pancreatic, rare cancer, ovarian cancer, or melanoma are prohibited and will not be accepted. The FY21 PRCRP requires all applications to answer at least one of the Military Health Focus Areas listed on the opportunity website.
Behavioral Health Science Award: Supports innovative research and high-reward concepts that span the spectrum of behavioral health science including prevention, survivorship, quality of life, and psychosocial research related to cancer. Value: Up to USD $1M for up to 4 years.
Career Development Award- Fellow Option: Supports independent, early-career investigators to conduct impactful research with the mentorship of an experienced cancer researcher. These are independent investigators at or above the level of Assistant Professor or Instructor (or equivalent) and within 7 years after completion of their terminal degree (excluding time spent in residency or on family medical leave) by the time of the application submission deadline. Value: Up to USD $400,000 for up to 3 years.
Career Development Award- Virtual Cancer Center Scholar Option: Supports the addition of new early-career investigators (Scholars) to the unique, interactive virtual cancer center focused on fostering the next generation of independent cancer researchers. These are independent investigators at or above the level of Assistant Professor or Instructor (or equivalent), on tenure track (or equivalent) and within 7 years after completion of their terminal degree (excluding time spent in residency or on family medical leave) by the time of the application submission deadline. Value: Up to USD $800,000 for up to 4 years.
Translational Team Science Award: Emphasizes multi-PI, multidisciplinary collaborations. Supports translational studies associated with an ongoing or completed clinical trial that can lead to a future clinical trial or clinical application in cancer research. Not intended to support high throughput screenings, sequencing, etc. Value: Up to USD $2.5M for up to 4 years.
Convergent Science Cancer Consortium Development Award: Infrastructure development to establish the necessary collaborations amongst a Coordinating Center and Research Sites. Multi-Institution collaboration required. Minimum of three separate institutes: one Coordinating Center and at least two Research Sites (other than the Coordinating Center). Value: Up to USD $2.5M for up to 2 years.
Behavioral Health Science Award, Career Development Award- Fellow Option, Career Development Award- Virtual Cancer Center Scholar Option, Translational Team Science Award: Pre-Application: July 12, 2022; Application: August 2, 2022.
Convergent Science Cancer Consortium Development Award: Pre-Application: August 17, 2022; Application: September 7, 2022.
InternationalNational Multiple Sclerosis Society (NMSS) Research GrantsNot specified; generally up to 3 years.These support research focused on addressing research questions highlighted in the Pathways to MS Cures Roadmap. The Roadmap includes three Pathways: STOPPING MS disease activity, RESTORING function by reversing damage and symptoms, and ENDING MS by preventing new cases.Pre-Application: July 13, 2022.
Full Application: July 20, 2022.
InternationalUS Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY22 Lung Cancer Research Program (LCRP): Clinical Translational Research Partnership AwardUp to USD $1.2 million for up to 3 years.
Supports translational studies that include an interventional clinical trial.Pre-Application: July 13, 2022.
Application: July 27, 2022.
InternationalGlaucoma Research Foundation (GRF): Shaffer Fund for Innovative Glaucoma ResearchUp to USD $50,000 for 1 year.This supports new high-impact clinical, epidemiological and laboratory research based on GRF’s strategic research goals: Protect and restore the optic nerve; Accurately detect glaucoma and monitor its progress; Find the genes responsible for glaucoma; Understand the intraocular pressure system and develop better treatments; Determine the risk factors for glaucoma damage using systematic outcomes data.Preliminary Proposal: July 15, 2022.
Application (by invitation): TBD. Invitations by September 2022.
InternationalThrasher Research Fund: E.W. "Al" Thrasher AwardsUp to USD $550,000 for up to 3 years.The purpose is to improve children's health through medical research, with an emphasis on projects that have the potential to translate into clinically meaningful results within a few years. Both incidence and severity are considered when determining the significance of the proposed topic. Concept Papers: July 19, 2022.
Full Proposal (by invitation): October 28, 2022.
InternationalSociety for Emergency Medicine (SAEM) Foundation (SAEMF): Various OpportunitiesRange from up to USD $4,000 to up to USD $150,000 per year for 1 or 2 years. These grants to help fund innovative research and education initiatives in the field of emergency medicine. Grants of various size and scope are available. Please see the SAEM Research Grants website for a list of the available grants.
NOTE: For all grants, the applicant must be a member of SAEM in good standing at application deadline and during the entire award period.
August 1, 2022.
InternationalAssociation for Academic Surgery (AAS) Joel J. Roslyn Faculty Research AwardUSD $50,000 for 1 year.This provides early-career research support to junior faculty members of the AAS. Applicants must be full-time faculty who have not yet attained the rank of Associate Professor and active members of the AAS.August 1, 2022.
InternationalSociety of Critical Care Medicine (SCCM) Research GrantsPlease see individual funding opportunity description.SCCM-Weil Research Grant: Awarded to SCCM Professional or Select members for basic, translational, or clinical research. Single-site clinical study. Value: USD $50,000 for up to 18 months.
Discovery Research Grant: Awarded to SCCM Professional or Select members for a Multi-institutional study (collaboration between at least two institutions). Value: USD $100,000 for up to 12 months.
August 1, 2022.
InternationalAmerican Foundation for Suicide Prevention (AFSP): Grant Cycle 2022Please see individual funding opportunity description.Focus Grant-Blue sky research grant: Supports an innovative, impactful study in an area of suicide research that will achieve significant goals. This mechanism is intended for studies that, by their very nature, are clearly beyond the financial scope of our Innovation Grants. Value: Up to USD $500,000 per year for up to 3 years.
Linked Standard Research Innovation Grants: For research involving two or more unique sites with each site contributing unique expertise, as well as data collection. Value: Up to USD $450,000 per year for up to 2 years.
Distinguished Investigator Innovation Grants: For investigators at the level of associate professor or higher with an established record of research and publication on suicide. Value: Up to USD $150,000 over 2 years.
Standard Research Innovation Grants: Grants awarded to individual investigators at any level. Value: Up to USD $125,000 over 2 years.
Early Career Researcher Innovation Grants: Grants awarded to investigators at or below the level of assistant professor. Value: Up to USD $110,000 over 2 years.
Pilot Innovation Grants: These provide seed funding for new projects that have the potential to lead to larger investigations. These grants typically entail feasibility studies rather than hypothesis-driven research. Value: Up to USD $50,000 over 2 years.
Focus Grant-Blue sky research grant: Letter of Intent: August 1, 2022; Full Application (by invitation): December 7, 2022.
Linked Standard Research Innovation Grants: Letter of Intent: September 15, 2022; Full Application (by invitation): November 15, 2022.
Distinguished Investigator Innovation Grants: November 15, 2022.
Standard Research Innovation Grants: November 15, 2022.
Early Career Researcher Innovation Grants: November 15, 2022.
Pilot Innovation Grants: November 15, 2022.
InternationalUpdated: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP) FY22 Breast Cancer Research Program (BCRP)Please see individual funding opportunity description.The BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity, and facilitate productive collaborations.
Transformative Breast Cancer Consortium Award II: Up to USD $25 million for up to 4 years.
Breakthrough Award II Levels 1 and 2: Funding Level 1: Up to USD $450,000 or up to USD $750,000 with the Partnering PI Option for up to 3 years; Funding Level 2: Up to USD $1 million for up to 3 years (up to USD $1.5 million for Population Science and Prevention Studies for up to 4 years). With the Partnering PI Option, up to USD $1.5 million for up to 3 years (or up to USD $2 million for Population Science and Prevention Studies for up to 4 years).
Breakthrough Award II Level 3 and Breakthrough Award Level 4: Funding Level 3: Up to USD $4 million or up to USD $5 million with the Partnering PI Option for up to 4 years; Funding Level 4: Up to USD $10 million for up to 4 years.
Era of Hope Scholar Award II: Up to USD $3 million for up to 4 years.
Innovator Award II: Up to USD $7 million for up to 4 years.
Transformative Breast Cancer Consortium Award II: Pre-Application: August 3, 2022; Invited Application: November 2, 2022.
Breakthrough Award II Levels 1 and 2: Pre-Application: September 22, 2022; Application: October 6, 2022.
Breakthrough Award II Level 3 and Breakthrough Award Level 4: Pre-Application: August 3, 2022; Invited Application: November 2, 2022
Era of Hope Scholar Award II: Pre-Application: September 22, 2022; Application: October 6, 2022; Confidential Letters of Recommendation: October 11, 2022.
Innovator Award II: Pre-Application: August 3, 2022; Invited Application: November 2, 2022; Confidential Letters of Recommendation: November 4, 2022.
InternationalAmerican Society of Colon and Rectal Surgeons (ASCRS) Research Foundation: Various OpportunitiesPlease see individual funding opportunity description.Research in Robotic Surgical Technology Grants: This is for research interests specifically germane to robotic surgical technology in the field of colon and rectal surgery. Value: USD $50,000 for 1 year; Up to USD $100,000 for 1 year for collaborative proposals that include 2 or more institutions.
International Fellowship Grants: This grant will focus on providing support to clinical investigators in the United States or Canada who would like to participate in research outside the United States or Canada. Value: USD $12,500 for 1 year.
General Surgery Resident Research Initiation Grants: Applicants must be General Surgical Residents or recent (within 2 years) Graduates of a US or Canadian approved General Surgery Training Program. Value: USD $20,000 for 1 year.
August 15, 2022.
InternationalBiogen: Various Opportunities--Biogen considers requests in Biosimilars (Dermatology, Gastroenterology, Ophthalmology, Rheumatology), Multiple Sclerosis, and Spinal Muscular Atrophy in these areas:
Medical Education: Supports independent medical educational activities for HCPs and researchers. Medical education may be accredited or non-accredited.
Patient Education: Supports independent educational activities for patients or caregivers.
General Grant: Supports a project or program that does not fit any of the other defined grant categories.
August 15, November 1.
International23andMe Research Innovation Collaborations Program--This pairs up academic researchers with 23andMe scientists to perform analyses. Through this program, academic researchers can access de-identified, aggregated data from the 23andMe Research Cohort. 23andMe is interested in proposals focused on topics that are of high significance for underrepresented populations, including groups with African, South/Central Asian, and Latinx ancestry.Rolling. Next deadline September 16, 2022.
InternationalPatient-Centered Outcomes Research Institute (PCORI): Improving Methods for Conducting Patient-Centered Outcomes ResearchUSD $750,000 for up to 3 years.PCORI aims to fund studies that address high-priority methodological gaps in patient-centered outcomes research (PCOR) and clinical comparative effectiveness research (CER). PCORI has identified the following areas as programmatic priorities:
- Methods to Improve the Use of Artificial Intelligence (AI) and Machine Learning (ML) in Clinical Research
- Methods to Improve Study Design
- Methods to Support Data Research Networks
- Methods Related to Ethical and Human Subjects Protections Issues in PCOR/CER
Letter of Intent: October 4, 2022.
Full Application: January 10, 2023.
InternationalAmerican Society of Hematology (ASH) Bridge Grant ProgramUSD $150,000 for 1 year.These are granted to ASH members who applied for an NIH R01 grant or equivalent and were scored but not funded. ASH Bridge Grants are intended to help sustain recipients' research and contribute to their retention in hematology investigation while they reapply.November 1, 2022.
InternationalOrthopaedic Research Society (ORS)/Orthoregeneration Network (ON) ON/ORS Kick-Starter GrantsUSD $10,000.These grants support research that focuses on an innovative approach in regenerative orthopaedics or that answers an important open question in that field. The topic is innovative techniques and materials for the regeneration of musculoskeletal tissues. Candidates must be ORS members at the time of application and have not benefited from an ON/ORS support program before.November 1, 2022.
InternationalMendez National Institute of Transplantation Foundation (MNITF) Research Grant Program (RGP)Up to USD $150,000 for up to 2 years.These grants support innovative research to advance the science and practice of organ transplantation. The focus of Immediate Impact funding is to benefit the transplant community through improved organ donor screening, organ quality assessment, and predictive indicators. The aim of Visionary Research funding is to provide grant opportunities that focus on longer-term goals with significant potential for future impact.Letter of Inquiry: November 1, 2022.
Application (by invitation): December 15, 2022.
InternationalBayer Hemophilia Awards Program (BHAP): Various OpportunitiesPlease see individual funding opportunity description.Clinical Research Award: Provides funds to undertake a clinical research project in the bleeding disorders field. Value: Up to USD $75,000 for 1 year.
Basic Research Award: Provides funds to undertake a basic research project in the bleeding disorders field. Value: Up to USD $75,000 for 1 year.
Patient Engagement Award: Provides funds to support efforts in the field of patient engagement, education and advocacy within hemophilia. It recognizes the essential role of nurses, allied healthcare professionals and caregivers in the care of patients with hemophilia. Value: Up to USD $25,000 for 1 year.
Letter of Intent: November 30, 2022.
Full Proposal (by invitation): February 2023.
InternationalResMed Foundation: Physician and Public AwarenessUSD $10,000.This is to further the awareness and knowledge of the inherent dangers of untreated sleep disordered breathing, its symptoms, diagnosis and treatment with sleep specialists, primary care physicians, educators and the general public. Only programs that have wide outreach to a significant clinical or public population base will be considered.December 15, 2022.
InternationalCystic Fibrosis Foundation (CFF): Various OpportunitiesPlease see individual funding opportunity description.CFF/NIH R01-Unfunded Award: This supports excellent cystic fibrosis-related research projects that have been approved by the National Institutes of Health (or governmental funding agencies in other countries) but cannot be supported by available funds. Value: Up to USD $125,000 per year for up to 2 years.
Path to a Cure - Pioneer Award: For ambitious basic research projects aiming to utilize cutting-edge techniques and strategies that have the potential to discover new genetic-based therapies for cystic fibrosis.
CFF/NIH R01-Unfunded Award: December 15, 2022.
Path to a Cure - Pioneer Award: Rolling.
InternationalPre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP): FY22 Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP)Please see individual funding opportunity description.Clinical Trial Award:Supports clinical trials for pharmacological (e.g., biologics, drugs) and non-pharmacological (e.g., devices, psychotherapy) interventions. Value: Funding Level 1: Up to USD $500,000 for up to 3 years; Funding Level 2: Up to USD $2.0M for up to 4 years; Funding Level 3: Up to USD $4.0M for up to 4 years.
Focused Program Award: Supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal. Value: Up to USD $5.0M for up to 4 years.
Investigator-Initiated Research Award: Supports research with the ability to make an original and important contribution to research and/or patient care. Value: Up to USD $500,000 for up to 3 years.
Translational Research Award: Supports the translation of promising research into clinical application (i.e., preclinical to clinical translation). Value: Up to USD $1.0M for up to 3 years.
Patient-Centered Research Award: Bridges the gap between research, practice, and policy by building a knowledge base on how interventions and clinical practices/guidelines and policies can be deployed to targeted populations at the appropriate time at the point of need. Value: Up to USD $1.0M for up to 3 years.
TBA
InternationalAlzheimer's Association: International Research Grant Program --Multiple OpportunitiesVarious
InternationalSolving Kids Cancer (SKC): Therapeutic Development Initiative (TDI) - Funding for High-Impact Pediatric Cancer Research$50,000 to $500,000 USD for up to 2 years.The TDI of SKC only supports clinical research.Preliminary Proposal Deadline: Ongoing
InternationalÖssur Orthopaedic Research Grant Program--This provides funding for scientific inquiry in the areas of lower extremity biomechanics, dynamic/active rehabilitation, ortho biologics, functional bracing, clinical patient outcomes, and, related healthcare economics.Rolling Deadline
InternationalGateway for Cancer Research (GFCR): Various OpportunitiesGFCR Grant Program: USD $200,000 to $1.5 million for 2-5 years

GFCR Integrative Program:USD $200,000 to $1.5 million for 2-5 years.

SIO / Gateway Integrative Research Grant Program: Value: USD $200,000 to $1.5 million for 2-5 years.
Gateway funds Phase I and II patient-centered cancer clinical trials that have the potential to shift the paradigm for standard of care, focusing on the following priority research areas: Biomarkers/Molecular Markers (genomic or proteomic); Gene Therapy; Histology Agnostic/Basket Trial; Immunotherapy; Targeted Therapies. Focus is on the following therapeutic areas: New Investigational Therapies; Novel Use or Approach; Precision Medicine; Integrative Medicine.

GFCR Grant Program: Funds early phase clinical trials for cancers of all types at renowned institutions around the world.

GFCR Integrative Program: Funds integrative oncology research that pairs conventional therapies with evidence-based integrative therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life, especially post-treatment.

SIO / Gateway Integrative Research Grant Program: Funds integrative oncology research that pairs conventional therapies with evidence-based integrative therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life, especially post-treatment.

GFCR Decentralized (DCTI) Grant Program: Leverages site-less, technology-informed trials, with the objective of bringing clinical trials directly to patients doorsteps.
GFCR Grant Program: Rolling Deadline

GFCR Integrative Program:Rolling Deadline

SIO / Gateway Integrative Research Grant Program: Rolling Deadline

InternationalAesculap Implant Systems Investigator-Initiated Study Program (IIS)--This supports researchers interested in conducting studies of their own design, which promotes the advancement of medical and scientific knowledge related to Aesculap's products and therapeutic areas of focus: Neurosurgery; Surgical Technologies; Closure Technologies; Orthopaedics; Spine; Biologics.Continuous intake
InternationalBausch + Lomb Grants--Educational Grants: These contribute to the improvement of patient care and advances in the use of healthcare products. Grand-rounds, lectures, symposiums and workshops are funded to educate medical students, university faculty, physicians, nurse practitioners, optometrists, ophthalmologists, allied health professionals, optical research scientists and associations of optometry and ophthalmology about improvements in ocular health.
Independent Research Grant: These empower the global research community to develop new treatments and technological advancements in ocular health. Research Grants have been funded by to improve consumers' standard of care, efficacy, patient satisfaction, safety and vision performance.
Rolling submission. Allow 6-12 weeks for proposal review and decision.
NIHNIH BRAIN Initiative: Standards to Define Experiments Related to the BRAIN Initiative (R01 Clinical Trial Not Allowed)--This aims to develop standards that describe experimental protocols conducted as part of the BRAIN Initiative. It is expected that applications will solicit community input at all stages of the process. It is recommended that the first step of standard development will involve sharing data between different key groups in the experimental community in order to ensure that the developing standard will encompass the data collection efforts of those groups. The developed standard is expected to be broadly disseminated for use and widely available.June 14, 2023; June 14, 2024.
NIHNIH Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)
--The study must address questions within the mission and research interests of the National Institute of Neurological Disorders and Stroke (NINDS) and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. NINDS is particularly interested in pragmatic study designs that utilize a cost-effective means of prospectively collecting observational data important to current clinical practice.June 17, 2022; October 18, 2022; February 17, 2023; June 19, 2023; October 18, 2023; February 20, 2024; June 18, 2024; October 18, 2024; February 19, 2025.
NIHNIH Translational Neural Devices (UG3/UH3 - Clinical Trial Optional)--This encourages investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.June 20, 2022; October 18, 2022; February 21, 2023; June 19, 2023; October 18, 2023; February 20, 2024.
NIHNational Cancer Institute (NCI) Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)--This grant supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, symptom management, or reduction of cancer health disparities. June 21, 2022.
NIHNIH Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery: Various Opportunities--This invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing.
- PAR-21-349 (R01 Basic Experimental Studies with Humans Required): Types of projects include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects of phenomena related to social connectedness and isolation. Applications should not propose a goal of clinical outcomes or products.
- PAR-21-350 (R01 Clinical Trials Not Allowed): For applications that propose studies including model animal research or observational studies involving humans. Both animal model and human subjects research projects are welcome; however, clinical trials are not allowed.
- PAR-21-352 (R01 Clinical Trial Required): Types of projects include mechanistic studies that are classified as clinical trials. Types of studies include clinical trials that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.
June 21, 2022; June 21, 2023; June 21, 2024.
NIHNIH Using Just-in-Time Adaptive Interventions to Optimize Established Adolescent Mental Health Treatments (R61/R33 Clinical Trial Required)--National Institute of Mental Health seeks applications for pilot research to develop and test just-in-time adaptive intervention augmentations to enhance the effectiveness and clinical potency of established adolescent mental health treatments. An emphasis is placed on studies that are informed by developmental science and grounded in an empirical model of behavior change.June 22, 2022; February 22, 2023.
NIHNIH NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)--This is for investigator-initiated exploratory Phase 1 and Phase 2 clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). These trials must address questions within the mission and research interests of the NINDS. They may include studies of drugs and biologics, feasibility or preliminary efficacy studies of devices, and early studies of surgical, behavioral or rehabilitation therapies.June 22, 2022; October 7, 2022; February 8, 2023; June 13, 2023; October 10, 2023; February 8, 2024; June 10, 2024; October 8, 2024; February 10, 2025.
NIHNIH BRAIN Initiative: Targeted BRAIN Circuits Projects--- R34 Clinical Trials Not Allowed:For applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifyingR34 Clinical Trials Not Allowed:: July 1, 2022; October 5, 2022; June 30, 2023; October 4, 2023; June 28, 2024; October 2, 2024.
R01 Clinical Trial Not Allowed: July 1, 2022; October 6, 2022; June 30, 2023; October 4, 2023; June 28, 2024; October 2, 2024.
NIHNIH HEAL Initiative: Discovery and Functional Evaluation of Human Pain-associated Genes and Cells (U19 Clinical Trial Not Allowed)--Supports research that uses human tissue or cells to generate comprehensive datasets for the discovery and characterization of functional genetic elements, epigenetic signatures, and molecular/cellular pathways that underlie human pain transduction, transmission, and processing.July 7, 2022; October 11, 2022; March 9, 2023.
NIHNIH Research on Current Topics in Alzheimer's Disease and Its Related DementiasThis invites applications proposing research on current topics in Alzheimer's disease (AD) and its related dementias (ADRD). Further information on the high-priority topics of interest will be announced through a series of Notices published subsequent to this announcement. Applications proposing research on topics beyond those specified in the notices will not be prioritized for funding.
- R21 Clinical Trial Optional: For applications that need additional preliminary data with broader dissemination to establish them for more general use in this research field.
- R01 Clinical Trial Optional
July 8, 2022; November 14, 2022; March 10, 2023; July 10, 2023; November 13, 2023; March 11, 2024; July 9, 2024; November 12, 2024.
NIHNIH Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed)--This supports exploratory studies developing or using novel tools or technologies or testing novel hypotheses to investigate mechanistic questions in HIV infection, replication, latency, and/or pathogenesis (including neuroHIV) in the context of Substance Use Disorders (SUDs). This initiative focuses on exploration and characterization of signaling pathways that are involved in CNS HIV establishment and expansion. This promotes research to investigate the underlying molecular mechanisms by which HIV infection is initiated, established, and maintained in the CNS and to determine how addictive substances modulate HIV infection, latency and the size and persistence of CNS HIV reservoirs.July 14, 2022; September 7, 2022.
NIHNIH Tobacco Regulatory Science (R01 Clinical Trial Optional)--This supports biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP).July 14, 2022; February 14, 2023.
NIHNIH Notice of Special Interest (NOSI): IMPROVE Initiative: Implementation Science to Advance Maternal Health and Maternal Health Equity

--This is to stimulate dissemination and implementation research on innovative approaches built on evidence-based findings from foundational research on factors that contribute to maternal morbidity and mortality. This NOSI will support the development and implementation of strategies to inform integrated efforts involving policy and practice changes to improve preconception, pregnancy, perinatal, and postpartum care and advance maternal health and maternal health equity.This notice applies to due dates on or after June 5, 2022 and subsequent receipt dates through July 17, 2022.
NIHIntegrative Research on Polysubstance Abuse and Disorder (R61/R33 Clinical Trial Optional)--The intent of this funding is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies.July 19, 2022; November 7, 2022
NIHNIH Enhancing HIV Reservoir Susceptibility to Elimination (R01 Clinical Trial Not Allowed)--This supports basic research to define cellular and molecular mechanisms within persistent HIV reservoir cells that promote survival and resistance to virus-induced and immune-mediated cell death, and to identify novel therapeutic targets that could sensitize HIV-infected cells to eradication strategies.August 3, 2022.
NIHNIH Accelerating the Pace of Drug Abuse Research Using Existing Data_This invites applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. Primary data collection is not allowed for applications.
- R21 Clinical Trial Optional
- R01 Clinical Trial Optional
August 5, 2022; November 15, 2022; March 7, 2023; August 9, 2023; November 15, 2023; March 4, 2024; August 5, 2024; November 15, 2024.
NIHNIH Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)--The National Institute on Drug Abuse (NIDA) CEBRA fosters highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research.August 10, 2022; March 8, 2023; August 10, 2023; March 8, 2024.
NIHNIH New Models of Integrated HIV/AIDS, Addiction, and Primary Care Service
--This supports the testing of enhanced models of care that optimally integrate HIV, addiction, and primary care services.
- PAR-20-273 (R01 Clinical Trial Required): This seeks applications that will test comprehensive service delivery models. Applicants needing to develop, refine, and/or test key components of such a model are encouraged to apply to the companion R34.
- PAR-20-274 (R34 - Clinical Trial Optional): The R34 grant mechanism is intended to encourage planning research by providing support for the initial development of a clinical trial or research project.
August 11, 2022; November 18, 2022; August 11, 2023
NIHNIH HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional)--This supports high priority research at the intersection of HIV and substance use. It is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research.August 15, 2022; February 15, 2023; August 15, 2023; February 15, 2024.
NIHNIH Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01 Clinical Trial Not Allowed)--This invites researchers to submit applications for support of clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. These studies should result in clinically validated biomarkers and clinical outcome assessment measures appropriate for use in upcoming clinical trials.August 18, 2022; February 17, 2023; August 17, 2023; February 20, 2024; August 19, 2024; February 19, 2025.
NIHNIH Urgent Awards: COVID-19 Mental Health Research--These aims to address urgent, time-sensitive mental health research questions related to COVID-19, including broader secondary impacts of the pandemic as well as research on the intersection of mental health, COVID-19, and HIV. Research supported will improve public health in the near term by informing responses to the current pandemic.
- R01 Clinical Trial Optional: Supports 1) understanding mechanisms by which mental illness impacts SARS-CoV-2 morbidity and mortality, 2) exploring how COVID-19 contributes to incident mental illness or HIV-outcomes, 3) identifying modifiable targets uniquely or robustly implicated in the pandemic that are relevant to new and worsening mental illness, and 4) conducting mechanistic trials probing biological or behavioral processes of those targets that may be pursued in future mental health therapeutic development.
- R01 Clinical Trial Required: Supports research to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions to respond to new and worsening mental illness and HIV-related outcomes among those who experience COVID-19 as well as the broader population impacted by the pandemic.
August 25, 2022; December 23, 2022.
NIHNIH Grand Opportunity in Medications Development for Substance-Use Disorders (U01 - Clinical Trial Optional)
--The purpose of this grant is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval.Applications will be accepted on a rolling basis, expiring on September 1, 2022.
NIHNIH Patient Activation for Self-Management of Chronic Conditions (R01 Clinical Trial Optional)--This encourages grant applications that address the influence of patient activation on self-management of chronic conditions.AIDS Applications: September 7, 2022; May 7, 2023.
New Applications: February 5, 2023.
NIHNIH Notice of Special Interest (NOSI): Research in the Emergency Setting--This notice invites basic, translational and clinical research and career development programs that effect all areas of emergency medical care, including injury and trauma. Please see opportunity details for the lists of NIH Institutes and Centers and associated funding opportunity announcements to use for submission of an application in response to this NOSI.This notice applies to receipt dates through September 8, 2022.
NIHNIH Notice of Special Interest (NOSI): COVID-19 Related School Disruptions Impact on Mental Health, Cognitive, Social, and Emotional Development of Children--This highlights interest in research to understand the mental health impact of the COVID-19 pandemic on school-aged children, specifically ages 3 - 12. Particularly, NIH is interested in the potential impact of primary instruction settings disruptions (e.g., pre-school, elementary school) on the mental health, cognitive, social, and emotional development of children. This notice applies to subsequent receipt dates through September 8, 2022.
NIHNIH National Library of Medicine Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional)

--The National Library of Medicine (NLM) supports innovative research and development in biomedical informatics and data science. The scope of NLM's interest in these research domains is broad, with emphasis on new methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, reusable approaches to discovery, curation, analysis, organization and management of health-related digital objects.Standard dates apply until September 8, 2022.
NIHNIH Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)--The primary objective is to move Digital Therapeutics (DTx) to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for Substance Use Disorders (SUDs). Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications.September 8, 2022; January 10, 2023; September 8, 2023; January 10, 2024.
NIHNIH Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research--This is for exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities.
- R61 Clinical Trial Not Allowed: This is suitable for projects that are at their inception, conceptual, or idea-based phase. In this phase, the technical feasibility of the proposed technology or methodology should not yet have been established.
- R33 Clinical Trial Not Allowed: This is suitable for projects that have overcome major feasibility gaps for the technology or methodology as demonstrated with supportive preliminary data but still require further development and rigorous validation to encourage adoption by the research community.
September 22, 2022.
NIHNIH Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)--This solicits applications from research partnerships formed by academic and industrial investigators to accelerate the development and adoption of promising bioengineering tools and technologies that can address important biomedical problems. The goal of the program is to support technological innovations that deliver new capabilities, which can realize meaningful solutions within 5-10 years. Projects may span the development in the research settings, validation, translation into clinical settings as needed, and incorporation of these solutions as endpoints into research protocols to enhance our understanding of life science processes or the practice of medicine to benefit patients.September 26, 2022; May 26, 2023; September 26, 2023; May 24, 2024; September 26, 2024.
NIHNIH HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)_The focus is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target.October 4, 2022; February 2, 2023; June 2, 2023; October 4, 2023; February 2, 2024; June 4, 2024; October 2, 2024.
NIHNIH Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed)

--This encourages innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness.October 5, 2022; February 5, 2023; June 5, 2023; October 5, 2023; February 5, 2024; June 5, 2024.
NIHNIH Dissemination and Implementation Research in Health: Various Opportunities--Supports studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.
- R01 Clinical Trial Optional
- R03 Clinical Trial Not Allowed
- R21 Clinical Trial Optional
R01 Clinical Trial Optional: October 5, 2022; February 5, 2023; June 5, 2023; October 5, 2023; February 5, 2024; June 5, 2024; October 5, 2024; February 5, 2025.
R03 Clinical Trial Not Allowed: October 16, 2022; February 16, 2023; June 16, 2023; October 16, 2023; February 16, 2024; June 16, 2024; February 16, 2025; June 16, 2025.
R21 Clinical Trial Optional: October 16, 2022; February 16, 2023; June 16, 2023; October 16, 2023; February 16, 2024; June 16, 2024; February 16, 2025; June 16, 2025.
NIHNIH Exploratory Grants in Cancer Epidemiology (R21 Clinical Trial Optional)

--This supports applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (e.g. epidemiologic, biomedical, behavioral, health care delivery or clinical).October 7, 2022; June 7, 2023; October 9, 2023; June 7, 2024; October 8, 2024
NIHNIH HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed)--This supports interdisciplinary team-based research projects to develop assays, conduct screening and early optimization work followed by pharmacokinetic, pharmacodynamic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development. Discovery and validation of pharmacodynamic markers as well as development and validation of animal models or outcome measures are also responsive.October 11, 2022; June 9, 2023; October 10, 2023.
NIHNIH Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)--The National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial.October 11, 2022; February 10, 2023; June 13, 2023; October 11, 2023; February 13, 2024; June 11, 2024; October 11, 2024.
NIHNIH NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)--This is to encourage grant applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies.October 11, 2022; February 9, 2023; June 9, 2023; October 10, 2023; February 9, 2024.
NIHNIH HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development (U19 Clinical Trial Not Allowed)--The goal of this funding opportunity announcement (FOA) is to support team-based research projects to develop assays, screening and early optimization work to develop a non-addictive therapeutic to treat pain. Discovery and validation of pharmacodynamic markers efficacy and pharmacokinetic / pharmacodynamic (PK/PD) studies are also responsive. This FOA is not specific for any one or group of pain conditions.October 11, 2022; June 9, 2023; and October 10, 2023.
NIHNIH HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed)--The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R34 applications that propose 2-year exploratory/planning awards. The limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application. October 11, 2022; June 9, 2023; and October 10, 2023.
NIHNIH Dementia Care and Caregiver Support Intervention Research--R01 Research Project Grant - Clinical Trial Required: This solicits mechanism-focused dementia care and caregiver support intervention development research at Stages I through V of the NIH Stage Model to address the care needs and promote the health, function, and well-being of persons with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) and of those providing their care.

R61/R33 - Clinical Trial Required: This will support pragmatic trials within Stage IV of the NIH Stage Model to improve dementia care across multiple dementia care settings. This will support Stage I or Stage III pilot research to test the feasibility of implementing and integrating interventions (R61 phase) that, if successful, can transition to an R33 phase (Stage IV) for implementation of large pragmatic trials.
October 11, 2022; February 10, 2023; October 10, 2023; February 13, 2024.
NIHNIH National Institute of Mental Health (NIMH) Clinical Trial Funding Opportunity Announcements (FOAs): Various Opportunities--NIMH solicits clinical trial applications through a series of FOAs that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials.
- PAR-21-129: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required)
- PAR-21-130: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)
- PAR-21-131: Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required)
- PAR-21-132: Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)
- PAR-21-134: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)
- PAR-21-135: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)
- PAR-21-136: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)
- PAR-21-137: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)
October 14, 2022; February 15, 2023; June 15, 2023; October 17, 2023; February 15, 2024.
NIHNIH Social Disconnection and Suicide Risk in Late Life--This encourages research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanisms to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental
- R21 Clinical Trial Optional: Most appropriate for high risk/high payoff projects that lack preliminary data.
- R01 Clinical Trial Optional: For applications with preliminary data.
October 15, 2022.
NIHNIH Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)



--This encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.November 8, 2022; March 7, 2023; November 5, 2023; March 7, 2024.
NIHNIH Informatics Technologies for Cancer Research and Management--This invites applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities.
- Development of Innovative Informatics Methods and Algorithms (R21 Clinical Trial Optional):This supports the development of novel informatics capabilities that involve a high degree of innovation that have the potential to accelerate or enhance research.
-Early-Stage Development (U01 Clinical Trial Optional):For initial tool development or the significant modification of existing tools for new applications.
-Advanced Development (U24 Clinical Trial Optional): For emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field.
-Sustained Support (U24 Clinical Trial Optional):This focuses on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources.
November 17, 2022.
NIHNIH Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed)



--This supports hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI).December 7, 2022; December 7, 2023; December 7, 2024.
NIHNIH Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI)--This supports studies that accelerate our understanding of the roles of complement components and/or receptors in the initiation, magnitude, maintenance, and quality of immune responses against infectious agents, or of the roles played by complement in the development of immune-mediated pathogenic responses following infection. The results of such studies will inform the development of adjuvants and vaccine candidates or therapeutics that target complement components.This notice applies to subsequent receipt dates through January 7, 2023.
NIHNIH Co-infection and Cancer
- PAR-20-062 (R01 Clinical Trial Not Allowed)
- PAR-20-061 (R21 Clinical Trial Not Allowed)
--The purpose is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents - either concurrently or sequentially- and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.Standard dates apply until January 8, 2023.
NIHNIH Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01 Clinical Trial Optional)--This encourages projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. This is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control.Standard dates apply until January 8, 2023.
NIHNIH Notice of Special Interest (NOSI): Promoting Pain Research Within the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Mission Areas--This NOSI invites research applications that focus on improving the understanding of mechanisms of acute and chronic pain, and enhancing knowledge that will help better prevent, manage and reduce pain and improve health equity of all populations suffering from acute or chronic pain caused by rheumatic, autoinflammatory, musculoskeletal, and skin diseases and conditions within the NIAMS mission.This notice applies to subsequent receipt dates through January 10, 2023.
NIHNIH Notice of Special Interest (NOSI): Neurological and Neurocognitive Sequelae from SARS-CoV-2 Infection and COVID-19 in Aging and Age-Related Neurodegeneration--The specific research objectives of this NOSI are to rapidly expand the knowledge base on acute and long-term neurological and neurocognitive sequelae of COVID-19. NIA encourages investigator-initiated new and resubmission applications for research activity codes (i.e., R21, R01, R03) to address significant questions about the neurological and neurocognitive impacts of COVID-19 infection in aging and the interaction in older adults of COVID-19 with comorbid conditions, including Alzheimer's disease (AD) and AD-related dementias (ADRD). This notice applies to subsequent receipt dates through May 7, 2023.
NIHNIH Notice of Special Interest (NOSI): Heart, Lung, Blood and Sleep Focused Ancillary Studies to Large Ongoing Clinical Studies (Revised)--This seeks to expand the breadth of scientific research on the clinical course, prevention and treatment of diseases within the mission of the National Heart, Lung, and Blood Institute (NHLBI) by leveraging ongoing clinical research studies through ancillary studies. The purpose is to invite research project applications to conduct focused ancillary studies to large ongoing clinical trials (including late-stage T4 implementation clinical trials), observational studies, and registries.This notice applies to subsequent receipt dates through May 8, 2023.
NIHNotice of Special Interest (NOSI): Adopting Techniques and Tools Developed from the BRAIN Initiative Toward National Institute of Mental Health (NIMH) Strategic Research Priorities--NIMH is encouraging the submission of applications proposing to use the following types of tools/technologies developed in the BRAIN Initiative:
- Technologies that enable causal in vivo behavioral neuroscience experimental designs to probe functions of neural circuits implicated in the above-mentioned behavioral domains
- Technologies that analyze and manipulate complex circuits with a goal to provide comprehensive circuit diagrams
- Technologies that monitor neural activity and in vivo behaviors
- Interventional tools
- Technologies that allow examination of developmental time course and/or sex differences in mental health-relevant circuit function
- Computational modeling approaches and data analysis
This notice applies to receipt dates through May 8, 2023.
NIHNotice of Special Interest (NOSI): Research on Rehabilitation Needs Associated with the COVID-19 Pandemic--The purpose of this NOSI is to encourage applications in three areas related to the intersection of COVID-19, the associated mitigation actions, and rehabilitation:
- Encourage research to address the rehabilitation needs of survivors of COVID-19
- Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions
- Understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and the associated mitigation actions on people with physical disabilities
This notice applies to receipt dates through May 8, 2023.
NIHNIH Notices of Special Interest (NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems--The Office of Disease Prevention and participating Institutes, Centers and Offices (ICOs) are issuing this Notice to communicate our interest in research examining how electronic nicotine delivery systems (ENDS) affect normal and disease states relevant to human cells, tissues, organs, and behaviors. Research on alternative nicotine and tobacco delivery systems [e.g., heated tobacco products (also called heat-not-burn)] will also be considered. Basic Mechanisms of Health Effects:This Notice applies to subsequent receipt dates through May 9, 2023.
Population, Clinical and Applied Prevention Mechanisms of Health Effects:This Notice applies to subsequent receipt dates through May 9, 2024.
NIHOccupational Safety and Health Research (R01)
--The purpose is (1) to develop an understanding of the risks and conditions associated with occupational diseases and injuries, (2) to explore methods for reducing risks and preventing or minimizing exposure to hazardous conditions in the workplace, and (3) to translate significant scientific findings into prevention practices and products that will effectively reduce work-related illnesses and injuries.Standard dates apply until November 18, 2023.
NIHNIH Notice of Special Interest (NOSI): Developing Digital Therapeutics for Substance Use Disorders --The National Institute on Drug Abuse (NIDA) seeks applications that stimulate research to support the development and testing of Digital Therapeutics (DTx) to treat Opioid Use Disorders (OUD) or Polysubstance Use Disorders (PUD) as stand-alone interventions or integrated with FDA-approved medication treatments.This notice applies to subsequent receipt dates through December 7, 2023.
NIHNIH Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)--This seeks to broaden and strengthen patient-centric translational research collaborations between basic and clinical researchers both within and outside NIH to accelerate and enhance translational science by promoting partnerships between NIH intramural investigators (e.g., those conducting research within the labs and clinics of the NIH) and extramural investigators (e.g., those conducting research in labs outside the NIH).PAR-21-342: Pre-application (recommended, not required). Deadlines: December 13, 2022; December 13, 2023.

NIHNIH Notice of Special Interest (NOSI): Understanding the effects of cancer and cancer treatment on aging trajectories and aging outcomes--This supports applications that aim to better understand the effects of a cancer diagnosis and subsequent cancer treatment on aging trajectories and aging outcomes. These include, but are not limited to:
- Investigation of aging trajectories associated with specific cancer treatments and identification of cancer survivors at risk for an "accelerated aging" phenotype;
- Examination of the effects of specific cancer treatments on aging biology that may alter aging trajectories or aging outcomes;
- Development and/or validation of tools, technologies, measures, or techniques for the identification of late-emerging effects and aging phenotypes among cancer survivors;
- Use of old and young animal models to determine the effects of established and newer cancer therapies on aging endpoints;
- Development and/or testing of interventions designed to prevent, mitigate or reverse the adverse aging-related effects of cancer and cancer treatments; and
- Development and/or testing of interventions focused on models and processes of care delivery to intervene at the intersection of cancer treatment and aging.
This notice applies to receipt dates through January 7, 2024.
NIHNIH Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers--This supports the secondary use of real-world data for Artificial Intelligence (AI)-based predictive modeling with the ultimate goal of improving early detection and risk assessment for abdominal cancers. This encourages applications proposing multi-institutional collaborative AI development approaches such as federated learning, which distributes the models to data-owners and aggregates the results without sharing the actual data.This notice applies to subsequent receipt dates through January 8, 2024.
NIHNIH Priority HIV/AIDS Research within the Mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R01 Clinical Trial Optional)
--This seeks to stimulate HIV/AIDS research within the mission of the NIDDK that align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding. Standard AIDS dates apply until January 8, 2024.
NIHNIH Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R21 Clinical Trial Not Allowed)
--This is for innovative basic and translational pilot research projects within the mission of the NIDDK that are aligned with NIH HIV/AIDS research priorities. These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding. Potential topics could address multiple overarching priorities. Standard AIDS dates apply until January 8, 2024.
NIHCancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)--This supports investigator-initiated clinical that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health.Standard dates apply until January 8, 2024.
NIHNotice of Special Interest (NOSI): Use of Predictive Analytics to Accelerate Late-Stage Implementation Research to Address Heart, Lung, Blood, and Sleep Disorders--National Heart, Lung, and Blood Institute (NHLBI) seeks to leverage existing data resources using Predictive Analytics Implementation Research (PAIR) that utilizes complex and innovative methodologies and modeling techniques to rely on integration of existing data to inform the designs (and often test) implementation strategies for heart, lung, blood, and sleep (HLBS) conditions. NHLBI also encourages applications which focus on the development of advance modeling techniques and data reporting, which would be publicly available and could be used to inform subsequent implementation strategies to address HLBS conditions.This notice applies to receipt dates through January 8, 2024.
NIHNIH Notice of Special Interest (NOSI): Navigating Pediatric to Adult Health Care: Lost in Transition-This encourages applications in high-priority research areas related to pediatric health care transition for youth with chronic physical/medical conditions or intellectual/developmental disabilities. Research applications that will advance our understanding of promising practices designed to facilitate successful health care transitions (HCT) from pediatric to adult care settings as well as barriers and facilitators to such transition are encouraged.This notice applies to subsequent receipt dates through January 8, 2024.
NIHNIH Notice of Special Interest (NOSI): Telehealth in Cancer Care--This supports investigator-initiated applications for conducting research on the use of telehealth in cancer-related care. Studies focused on populations that experience inequities in access to care and have worse cancer outcomes compared to the general population are strongly encouraged.This notice applies to subsequent receipt dates through March 8, 2024.
NIHNIH Notice of Special Interest (NOSI): Validation of Digital Health and Artificial Intelligence Tools for Improved Assessment in Epidemiological, Clinical, and Intervention Research



--This encourages grant applications to support the evaluation of the utility and validity of digital health and artificial intelligence (AI) tools and technologies in epidemiological, clinical, and intervention research. The intent is to support the addition of new measurement modalities to evaluate existing and recently developed but not yet validated digital health and AI tools such as sensor technologies, smartphone applications, software as a medical device (SaMD), and AI algorithms.This notice applies to due dates on or after March 7, 2022 and subsequent receipt dates through March 9, 2024.
NIHNIH Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes--National Institute of Mental Health (NIMH) seeks applications to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus and intensity/burden.

PAR-21-211 (R34 Clinical Trial Required): This supports pilot research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches and inform the design of definitive effectiveness trials.

PAR-21-210 (R01 Clinical Trial Required): This supports fully-powered, definitive effectiveness studies focused on post-acute phase interventions
Standard dates apply until March 17, 2024.
NIHNIH Notice of Special Interest (NOSI): HIV Drug Resistance Assays and Actionable Data Dissemination Strategies--National Institute of Allergy and Infectious Diseases (NIAID) is interested in the development and optimization of next generation methodologies for HIV-1 drug resistance (DR) mutation detection and reporting. Strategies applicable to low and middle income countries as defined by the World Bank are especially encouraged.

National Institute on Drug Abuse (NIDA) is interested in the following areas: Feasibility of self-administered, cost effective, and potential for mail-in testing and follow up through mobile technologies targeting substance-using populations living with HIV; Development of technologies that allow sensitive and rapid read out of drug resistance; Plans for post-administering surveys to assess rates of access, acceptability (stigma and ethical concerns), accuracy, and treatment outcomes; Technologies that are easily adaptable for implementation in homeless shelters, community clinics, criminal justice, and emergency department settings.
This notice applies to due dates on or after September 5, 2021 and subsequent receipt dates through May 7, 2024.
NIHNIH Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)--This supports exploratory and innovative research projects, which fall within the missions of the NINDS and NIMH. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community.Standard dates apply until May 8, 2024.
NIHNIH NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)--This supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. Standard dates apply until May 8, 2024.
NIHNotice of Special Interest (NOSI) regarding the Use of Human Connectome Data for Secondary Analysis--This encourages secondary analyses of data from the Human Connectome Project (HCP), including the multiple datasets in the Lifespan Human Connectome projects and the Human Connectomes Related to Human Disease. Applicants beyond the groups that originally collected the data are encouraged to apply. The analyses will serve to generate and evaluate hypotheses about the complex interrelationships among: brain structure, function and connectivity; cognitive, affective, sensory and motor processes; environmental factors; life event, social and psychosocial factors; genomic data, and clinical symptoms during development, aging, or disease.This notice applies to receipt dates through May 8, 2024.
NIHNIH Notice of Special Interest (NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments--and control in low- and middle-income countries. NCI encourages applications that pursue innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines in low-resource settings.This notice applies to application due dates on or after October 5, 2022, and subsequent receipt dates through May 8, 2024.
NIHNIH Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): Various OpportunitiesUp to USD $50,000 per year for up to 2 years. PA-21-231 (R03 Basic Experimental Studies with Humans Required): This is for basic science experimental studies involving humans. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research.

PA-21-221 (R03 Clinical Trial Required): This supports clinical trials that fall within the NICHD mission.
Standard dates apply until May 8, 2024.
NIHNIH Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment--The purpose is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. Each partnership should include at least one academic and one industrial organization.

PAR-21-166: R01 - Clinical Trial Not Allowed
PAR-21-206: R01 - Clinical Trial Optional

Standard dates apply until May 8, 2024.
NIHNIH Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity: Various Opportunities--The purpose of these Funding Opportunity Announcements (FOAs) is to lay the groundwork for developing interventions at the network/circuit level that might be used as potential treatments for cognitive, affective, or social deficits in psychiatric disorders. These FOAs support projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing.

PAR-21-175 (R01 Clinical Trial Optional)
PAR-21-176 (R21 Clinical Trial Optional)
Standard dates apply until May 8, 2024.
NIHNIH Notice of Special Interest (NOSI) HIV/AIDS in the Era of COVID-19: When Pandemics Collide--This is to communicate special interest in epidemiology investigations to quantify the impact of the COVID-19 pandemic on HIV prevention, incidence, transmission, and outcomes. This NOSI encourages research on the impact and strategies needed to adapt the HIV/AIDS response through agile and innovative support of prevention and care and the maintenance of sustained HIV viral suppression during the COVID-19 pandemic.This notice applies to due dates on or after September 7, 2021 and subsequent receipt dates through May 8, 2024.
NIHNIH Notice of Special Interest (NOSI): Promoting Vaccine Access, Acceptance and Uptake among Children, Adolescents, Pregnant and Lactating Women, and Persons with Disabilities--This NOSI encourages applications that address dimensions of access, acceptance and uptake of CDC-recommended vaccines among infants, children, adolescents, pregnant and lactating women, and persons with disabilities, especially among populations who are underserved or experience health disparities.This notice applies to due dates on or after September 8, 2021 and subsequent receipt dates through May 8, 2024.
NIHNIH Notice of Special Interest (NOSI) - Emerging and Existing Issues of Coronavirus Disease 2019 (COVID-19) Research Related to the Health and Well-Being of Women, Children and Individuals with Physical and/or Intellectual Disabilities--The purpose is to provide an avenue for researchers to pursue funding to conduct research addressing emerging and existing COVID-related issues among pregnant and lactating people, infants, children and adolescents, and individuals with physical and/or intellectual disabilities. Please see the NOSI for the areas of interest in these populations.This notice applies to due dates on or after June 5, 2022 and subsequent receipt dates through June 6, 2024.
NIHNIH Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health--This calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels.This notice applies to subsequent receipt dates through June 8, 2024.
NIHNotice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)--This NOSI seeks to support investigation into the factors and molecular mechanisms that address the heterogeneity dictated by the host resilience. Research on general host responses to injurious challenges and their effects on lung function as well as mechanisms that impact susceptibility to ARDS is not considered to be responsive to this announcement.This notice applies to receipt dates through July 5, 2024.
NIHNIH Notice of Special Interest (NOSI): Using Data to Advance HIV Epidemic Knowledge and Program Planning--This encourages grant applications proposing research that makes use of available, large data sets with the objective of improving HIV epidemic modeling and service planning, with greater attention to the role of substance use. National Institute on Drug Abuse (NIDA) is interested in applications that make use of existing data, such as epidemiologic cohorts, clinic cohorts and longitudinal follow-up studies of interventions, as well as other publicly available sources of data including data warehouses and commercial data sources. Substance use should be a key component of any research supported by this NOSI.This notice applies to subsequent receipt dates through September 7, 2024.
NIHNIH Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19--National Institute on Drug Abuse (NIDA) is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19. This notice applies to due dates through September 7, 2024.
NIHNotice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection--This NOSI encourages research to understand:
- The risks that smoking or vaping tobacco or marijuana may have on acquiring the COVID-19 infection.
- The medical consequences, co-morbidity, and complications of COVID-19 infection in individuals who smoke or vape tobacco or marijuana.
- The medical consequences of COVID-19 in individuals who smoke and vape with comorbid conditions such as: SUD, HIV and other immunosuppressive diseases, mental health disorders, diabetes mellitus, obesity, cardiovascular, pulmonary, renal, and hepatic pathologies, as well as cancer.
This notice applies to due dates through September 8, 2024.
NIHNIH Basic Research in Cancer Health Disparities--This encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities.
- R01 Clinical Trial Not Allowed: These research project grants will support innovative studies designed to investigate biological/genetic bases of cancer health disparities.
- R21 Clinical Trial Not Allowed: This provides support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as R01 projects) of the biology of cancer health disparities.
- R03 Clinical Trial Not Allowed These small research grants will support projects on cancer health disparities that can be carried out in a short period of time with limited resources.
Standard dates apply until September 8, 2024.
NIHNIH Notice of Special Interest (NOSI): Behavioral Economics for Implementation Research (BEIR) to improve use of Evidence-Based Practices for heart, lung, blood, and sleep (HLBS) conditions



--National Heart, Lung, and Blood Institute (NHLBI) encourages applications that recognize the importance of cultural context, patterns of behavior change, and motivators for change across decision-making levels, including individuals (e.g., patients, parents, clinicians, others), groups, healthcare systems and/or communities.This notice applies to subsequent receipt dates through September 8, 2024.
NIHNIH Notice of Special Interest (NOSI): International Research Collaboration on Drug Abuse and Addiction Research



--The purpose of this notice is to encourage collaborative research applications that take advantage of opportunities outside of the US. Applications examining all areas of National Institute on Drug Abuse (NIDA)-supported research addressing the causes, consequences, treatment, and prevention of drug use, misuse, and addiction are encouraged. Projects should be conducted through newly formed or well-established partnerships between an investigator in a US-based institution and a scientist working in another country.This notice applies to subsequent receipt dates through September 8, 2024.
NIHNIH Notice of Special Interest (NOSI): Research on Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatment--The purpose is to stimulate research that identifies effective strategies for improving interprofessional teamwork and addresses care coordination challenges within care settings and between care settings (e.g., between tertiary care and community settings) or during care transitions (e.g., from inpatient to outpatient care). Research in this area should advance actionable knowledge about how to design and carry out effective, efficient interprofessional team-based cancer care that improves quality and patient outcomes. Research that is focused on the needs of racial/ethnic minority, medically underserved, or low-income populations and/or those receiving care in community settings (including, but not limited to, community-based cancer centers or clinics) is not required, but strongly encouraged.This Notice applies to subsequent receipt dates through October 9, 2024.
NIHNIH Clinical Trial Readiness for Functional Neurological Disorders (FNDs) (U01 Clinical Trial Optional) --This invites researchers to submit prospective clinical projects that address critical needs for clinical trial readiness in FNDs. Projects appropriate for this funding opportunity announcement include the validation of biomarkers, endpoints and clinical outcome assessments that are fit-for-purpose and have a defined context of use for clinical trialsStandard dates apply until November 6, 2024.
NIHNIH Neuromodulation/Neurostimulation Device Development for Mental Health Applications--This encourages applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently FDA-approved or cleared.
- R01 Clinical Trial Not Allowed: For applicants who seek to propose a larger project. Applicants who seek to establish proof-of-concept should respond to the companion R21.
-R21 Clinical Trial Not Allowed: This uses the R21 grant mechanism, encouraging shorter, higher-risk applications. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope.
Standard dates apply until January 8, 2025.
NIHNIH Drug Discovery for Nervous System Disorders --NIMH, NIAAA, NIDA and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics ; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.
- R01 Clinical Trials Not Allowed: Applicants with preliminary data may wish to apply using the R01 mechanism. High risk/high payoff projects that lack preliminary data may be most appropriate for the R21 mechanism.
- R21 Clinical Trials Not Allowed: This will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies).
Standard dates apply until January 8, 2025.
NIHNIH Notice of Special Interest (NOSI): COVID-19 Pandemic Mental Health Research --National Institute of Mental Health (NIMH) is issuing this NOSI to highlight interest in basic, translational, intervention and services research relevant to the COVID-19 pandemic. NIMH is especially interested in research to provide an evidence base to understand how mental illness contributes to COVID-19 risk and mortality, how incident mental illness develops with COVID-19, and the development of scalable interventions to meet the public mental health needs during and resulting from the pandemic both specifically related to the virus but also at a broader population level that is impacted by stress, disruptions, and loss of lives in the pandemic. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH. Research is anticipated to focus on particularly vulnerable populations based on existing evidence of increased mental health symptoms and illness and preexisting and worsening health disparities.This Notice applies to due dates on or after February 15, 2022 and subsequent receipt dates through January 8, 2025.
NIHNIH Notice of Special Interest (NOSI): Public Health Research on Cannabis --The National Institute on Drug Abuse (NIDA) is issuing this notice to encourage grant applications on the effects of changing cannabis laws and policies in the US and globally on public health.This notice applies to subsequent receipt dates through May 5, 2025.
NIHNIH Laboratories to Optimize Digital Health (R01 Clinical Trial Required) --This is intended to support the development of digital health test beds that leverage well-established digital mental health platforms and infrastructure to rapidly refine and optimize existing evidence-based digital health interventions and to conduct clinical research testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness particularly in populations who experience health disparities and vulnerable populations.Standard dates apply until May 8, 2025.
NIHNIH Notice of Special Interest (NOSI): Research to Prevent Drug Use, Misuse and Addiction --The National Institute on Drug Abuse (NIDA) is issuing this Notice to encourage grant applications in research on the prevention of risky drug use behaviors and addiction. The research may include studies to: 1) develop and test strategies to prevent the initiation of substance use, progression to substance use disorders, or to prevent substance use-related conditions such as HIV; 2) develop and test processes or strategies to implement, scale, and sustain evidence-based prevention in community, practice, and service systems;and,3) develop methods to conduct prevention science. Primary outcomes of interest for submitted applications include preventing initiation of substance use, misuse, and progression to disorder, as well as prevention of HIV infection.This notice applies to subsequent receipt dates through May 8, 2025.
NIHNIH Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening --This encourages translational research aimed at filling identified knowledge gaps to expand the evidence base for evaluating the balance of benefits and harms for proposed preventive screenings. At minimum, the proposed study must: Focus on a screening service that has not received a definitive grade or recommendation from organizations issuing evidence-based recommendations; and, include a measurable health outcome.This notice applies to due dates on or after June 15, 2022 and expires on May 8, 2025.
NIHNIH Notice of Special Interest (NOSI): Increasing Uptake of Evidence-Based Screening in Diverse Populations Across the Lifespan --This encourages highly innovative translational research focused on the delivery of multilevel interventions to improve uptake of evidence-based screening services that promote health equity and that are recommended by expert committees. At minimum, the proposed studies must: Include screening as a primary outcome; Inform the development of OR test an intervention or strategy that acts on at least two socioecological levels; and, Include OR test an intervention or strategy that demonstrates high potential for scalability and sustainability.This notice applies to due dates on or after June 15, 2022 and expires on May 8, 2025.
NIHNIH NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed) --The purpose is for secondary data analysis using existing data sets from vision-related clinical trials, epidemiologic, and other clinical research studies. This may be used to develop new statistical methodologies or test hypotheses using existing data, but must not be used to support the collection of new data.Standard dates apply until May 8, 2025.
NIHNIH NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed) --This supports applicants in their planning efforts to conduct collaborative large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies on eye/vision conditions. The grant may be used to support the development of a Manual of Procedures (MOP), as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention.Standard dates apply until May 8, 2025.
NIHNIH Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed)--This encourages innovative pilot research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial pilot projects that address National Institute of Mental Health (NIMH) strategic priorities to strengthen the public health impact of NIMH-supported research as described in Goal 4 of the NIMH Strategic Plan.Standard due dates apply until May 8, 2025.
NIHNIH Notice of Special Interest (NOSI): Diagnostics and Disease Management Tools for Use in Underserved Populations --This seeks applications for diagnostics and disease management tools that have the power to deliver breakthroughs to enable prevention and treatment of heart, lung, blood and sleep diseases in underserved communities. Investigators will be required to engage community partners at the onset and throughout their research project.This notice applies to due dates on or after February 5, 2022 and subsequent receipt dates through July 6, 2025.
NIHNIH Notice of Special Interest (NOSI): Epidemiology of Drug Abuse--This encourages the submission of research project applications that enhance our understanding of the nature, extent, distribution, etiology, comorbidities, and consequences of drug use, misuse, and addiction across individuals, families, communities, and diverse population groups. Of interest are applications that address multiple levels of risk, resilience, and causation across scientific disciplines, and that apply novel methods to advance knowledge of the interplay among genetic, environmental, neurobiological, and developmental factors and associated health and disease outcomes.This Notice applies to applies to due dates on or after June 5, 2022 and subsequent receipt dates through September 8, 2025.
NIHNIH Notice of Special Interest (NOSI): Leveraging Data Science to Bring Actionable Insights for Substance Use Prevention and Treatment --This supports research projects that 1) leverage data science to provide actionable insights for substance use prevention and treatment, 2) shorten the time between data capture and data availability so that data are available real-time or near real-time, and 3) explore methods and tools that may allow for faster or better localized responses for substance use treatment and prevention. Priority will be given to projects that emphasize the use of existing data streams (e.g., electronic health records, syndromic surveillance, claims data, registry data, pharmacy dispensing, social media, and mortality records).This notice applies to subsequent receipt dates through September 8, 2025.
NIHNIH Notice of Special Interest (NOSI): Development and Implementation of Clinical Informatics Tools to Enhance Patients’ Use of Genomic Information--This encourages applications to develop and implement patient-facing genomic-based clinical informatics tools that facilitate or enhance patient-provider electronic communication, patient tracking and registry functions, patient self-management and support, provider electronic prescribing, test tracking, referral tracking, and health care decision-making.This notice applies to subsequent receipt dates through September 24, 2025.
NIHNIH Notice of Special Interest (NOSI): Promoting Cardiovascular and Cardiometabolic Health in Early Stages of the Lifecourse: Pre-adolescence Through Adolescence to Young Adulthood --This supports support research to: 1) understand the mechanisms and the pathogenesis of cardiometabolic health and cardiovascular disease (CVD) risk in vulnerable groups throughout transitionary phases, from pre-adolescence (6-10 years) through adolescence (11-18 years) to young adulthood (19-39 years), and 2) develop precision prevention interventions (at the individual and populations levels) to address cardiovascular and cardiometabolic risk across these transitionary phases.This notice applies to subsequent receipt dates through June 5, 2026.
NIHNIH Parent Announcements --- NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- NIH Research Project Grant (Parent R01 Clinical Trial Required)
- NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
Standard dates apply unless otherwise stated.